Theravance Biopharma, Inc.

Form 4

February 09, 2015

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

Washington, D.C. 20549

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations

may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

Theravance Biopharma, Inc. [TBPH]

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* HAUMANN BRETT K

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

(Last)

(Instr. 3)

Shares

(First)

(Middle)

3. Date of Earliest Transaction

(Month/Day/Year)

02/05/2015

Director 10% Owner X\_ Officer (give title Other (specify below)

(Check all applicable)

C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD

(Street)

4. If Amendment, Date Original

Α

SVP, Clinical Development 6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year) Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

D

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

**SOUTH SAN** FRANCISCO, CA 94080

(City) (State) (Zip) 2. Transaction Date 2A. Deemed 1. Title of Security (Month/Day/Year) Execution Date, if

4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Owned Following Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

(A)

135,000

or

\$0

Transaction(s) (Instr. 3 and 4)

Code V Amount Ordinary 02/05/2015

Price (D)

Α

140,714 (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(9-02)

#### Edgar Filing: Theravance Biopharma, Inc. - Form 4

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) |                                   |                     | ate             | 7. Title and<br>Amount of<br>Underlying<br>Securities | nt of<br>lying<br>ities | 8. Price of Derivative Security (Instr. 5) | 9. Nu<br>Deriv<br>Secur<br>Bene |
|---|---|---|---|--|-----------------------------------|---------------------|-----------------|---|-------------------------|--|---------------------------------|
|   | Derivative<br>Security                      |   |   |  | Securities<br>Acquired            |                     |                 | (Instr.   | 3 and 4)                |  | Owne<br>Follo                   |
|   |   |   |   |  | (A) or<br>Disposed                |                     |                 |   |                         |  | Repo<br>Trans                   |
|   |   |   |   |  | of (D)<br>(Instr. 3,<br>4, and 5) |                     |                 |   |                         |  | (Instr                          |
|   |   |   |   |  | 4, and 3)                         |                     |                 |   | Amount                  |  |                                 |
|   |   |   |   |  |                                   | Date<br>Exercisable | Expiration Date | Title   | or<br>Number<br>of      |  |                                 |
|   |   |   |   | Code V                                 | (A) (D)                           |                     |                 |   | Shares                  |  |                                 |

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

HAUMANN BRETT K C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080

SVP, Clinical Development

## **Signatures**

Brett K Haumann 02/09/2015

\*\*Signature of Date Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 5,714 shares acquired in a pro rata distribution by Theravance, Inc.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2